Where conviction is rising: ETH, addiction meds, bandwidth, and boring moats
Look at the biggest adds and you see a manager leaning hard into non‑consensus cyclicals and new structural winners. This isn’t window dressing — it’s a deliberate reset of what drives returns here.
- INDV (Indivior Pharmaceuticals, 6.76%, $83.6M): A top‑three stake installed in one shot. Mangrove is explicitly paying up for a controversial addiction‑treatment franchise and litigation overhang, then letting mean re‑rating do the work; the position sits about 169.9% above their average cost, suggesting they’ve been pressing strength rather than trimming success.
- ETH (Grayscale Ethereum Staking, 5.71%, $70.6M): A new core bet that crypto infrastructure is investable, and that the next leg of returns comes from yield‑bearing ETH exposure rather than meme beta. They’re currently down about 11.9% versus cost — and have not flinched — implying they view near‑term volatility as noise, not a thesis breach.
- OKE (ONEOK, 3.38%, $41.7M) and PCG/CIG alongside it: Building a cluster of regulated and quasi‑regulated energy and power cash flows. The OKE entry at scale signals a view that midstream volumes and dividends win in a stagflation‑ish or higher‑for‑longer backdrop.
- TIGO (Millicom, 3.38%, $41.7M): A 7,091.6% position size jump is not tinkering — it’s a statement. Mangrove is betting that under‑invested emerging‑market telecoms finally get paid for the capex they’ve sunk into bandwidth, helped by balance‑sheet repair and asset sales.
- KDP (Keurig Dr Pepper, 2.91%, $35.9M), UNP (Union Pacific, 2.91%, $35.9M), and GPC (Genuine Parts, 2.71%, $33.5M): A fresh trio of oligopolistic cash‑flow machines in beverages, rails, and auto parts. GPC is sitting roughly 18.8% below Mangrove’s entry, and yet it was added as a new stake — a clear signal they’re willing to underwrite near‑term mark‑to‑market pain for multi‑year pricing power.
- BILL and FIS (both meaningfully increased) plus TRIP (up 4,753.5% in shares): they are doubling down on transaction and travel rails that have disappointed the market, with BILL and TRIP trading 18.6–25.3% below Mangrove’s average buys. This is classic value‑through‑time‑arbitrage — leaning into hated software and travel networks they believe can re‑accelerate margins.
Taken together, the “big buys” tilt the fund toward three themes: crypto and digital rails as a new asset layer, essential networks (telecom, midstream, rails) with latent pricing power, and battered but resilient consumer/SMB software.
Conviction
The big buys
The biggest dollar adds this quarter — where conviction is rising.
| Position | Change | Portfolio weight | Value |
|---|---|---|---|
| INDVINDIVIOR PHARMACEUTICALS INC | New+$83.6M | 6.8% | $83.6M |
| ETHGRAYSCALE ETHEREUM STAKING | New+$70.6M | 5.7% | $70.6M |
| OKEONEOK INC NEW | New+$41.7M | 3.4% | $41.7M |
| TIGOMILLICOM INTL CELLULAR S A | Added 7091.6%+$41.1M | 3.4% | $41.7M |
| KDPKEURIG DR PEPPER INC | New+$35.9M | 2.9% | $35.9M |
| UNPUNION PAC CORP | New+$35.9M | 2.9% | $35.9M |
| GPCGENUINE PARTS CO | New+$33.5M | 2.7% | $33.5M |
| TRIPTRIPADVISOR INC | Added 4753.5%+$10.1M | 0.8% | $10.3M |
Dollar changes estimated at current prices (shares added × current price); top-50 current positions only.
What they’re trimming: SPAC housekeeping, not a thesis reversal
On the surface, Mangrove’s “biggest trims” look trivial — the cuts to FACT and IPOD barely register in dollars. That’s exactly the point: this quarter’s selling is about housekeeping and funding, not about repudiating core theses.
- FACT (FACT II Acquisition) and IPOD (DUNE Acquisition II): Reductions of 2.5% and effectively flat, respectively, free almost no capital but telegraph where conviction is not rising. These blank‑check structures are being left to amortize toward trust value rather than grown as risk assets.
- The broader SPAC sleeve (AIIA, OYSE, APAD, INAC, etc.) is largely unchanged in share count, despite attractive marks versus Mangrove’s low entry costs. That suggests they view this bucket as a balance‑sheet tool — carry and optionality with limited downside — rather than an area to press when new ideas like INDV, ETH, and TIGO demand fresh capital.
The real “trims” this quarter are visible in the sector weights, not in individual deletions from the top‑50. Finance, real estate, and consumer discretionary collectively shrink as a share of the book, implying that exits and reductions were more meaningful in positions now too small to appear in the top‑50 set. The absence of any major core‑name liquidation is itself telling: the manager is rotating at the edges, not capitulating at the center.
How exposure is rotating: out of credit and cyclicals, into crypto and cash flows
The bar chart makes the rotation unambiguous. Finance drops from 22.21% to 13.9% of the disclosed book, while real estate falls from 10.74% to 6.85% and consumer discretionary from 24.47% to 17.34%. This is a manager walking away from credit‑sensitive and advertising‑exposed stories toward assets whose value is set more by throughput and regulation than by GDP.
On the other side of the ledger, health care goes from effectively zero to 8.69% on the back of INDV alone, and telecom leaps from 0.11% to 4.33% via TIGO. Utilities nudge up to 9.4% with the addition of OKE, while consumer staples appears as a new 3.73% sleeve anchored by KDP. These shifts point to a view that the next few years will reward companies that can either raise price on inelastic demand or are regulated to earn a fair return.
The “Unclassified” bucket swells from 9.84% to 16.84%, driven by ETH, BSOL, and a cohort of SPACs and yieldy trust‑like vehicles. Under the hood, that’s effectively an allocation to crypto, optionality, and pseudo‑cash — a barbell against the more traditional industrial and utility names. Technology edges down from 8.7% to 6.71%, but the mix inside tech shifts toward idiosyncratic event and operating‑leverage stories (BILL, TRIP, OTEX) rather than broad platform exposure.
Forward read: a portfolio positioned for choppy nominal growth and idiosyncratic upside
Put it together and Mangrove is positioning for a world of stubborn nominal growth, volatile rates, and highly dispersed equity outcomes. They are de‑emphasizing balance‑sheet and credit spread plays, and leaning into businesses whose economics ride on usage, volume, and regulated returns — rails, telecom, midstream, beverages — plus a high‑beta crypto overlay via ETH and BSOL.
The willingness to add into drawdowns (ETH, BILL, FIS, TRIP, GPC) while pressing winners like INDV and TIGO suggests a time‑horizon edge: they’re comfortable being early and uncomfortable owning consensus defensives. Expect future 13Fs to show more of this barbell — crypto and digital rails on one side, dull cash‑flow franchises on the other — with the SPAC and trust sleeve continuing to serve as a self‑funding reservoir.
For observers, the key tell going forward will be whether the finance and real‑estate weights keep bleeding lower while health care, utilities, and telecom creep higher. If they do, Mangrove is effectively calling for a regime where regulated and semi‑regulated pipes — for energy, data, payments, and even addiction treatment — outperform broad market beta, with crypto as the torque on top.
Rotation
How the book's themes shifted
Portfolio weight by theme, this quarter versus last.
Frequently asked questions
What did Mangrove Partners Im Llc buy in 2026-Q1?+
Mangrove’s biggest new buys in 2026-Q1 were Indivior Pharmaceuticals, Grayscale Ethereum Staking (ETH), ONEOK, Keurig Dr Pepper, Union Pacific, Genuine Parts, and several new SPACs such as HAVA, CTAAU, KTWO, RFAM, GIXXU, SCII, XFLHU, IGAC, and IRHO.
What is Mangrove Partners Im Llc’s largest holding by portfolio weight?+
Indivior Pharmaceuticals is the largest disclosed position at 6.76% of the reported 13F portfolio, slightly ahead of Atmus Filtration (6.04%) and Grayscale Ethereum Staking (5.71%).
How is Mangrove Partners Im Llc rotating its sector exposure?+
The fund is reducing exposure to finance, real estate, and consumer discretionary while increasing allocations to health care, telecom, utilities, consumer staples, and an “unclassified” bucket dominated by crypto and SPAC-related holdings.
Is Mangrove Partners Im Llc bullish on cryptocurrencies?+
Yes. A new 5.71% position in Grayscale Ethereum Staking and an increased stake in Bitwise Solana Staking ETF signal a deliberate crypto allocation, even as ETH currently trades below the fund’s average cost.
How did Mangrove Partners Im Llc perform over the latest quarter and longer term?+
The 13F portfolio was down 4.45% in 2026-Q1, but the weighted 3-year annualized return is 32.89% (134.67% cumulative) and the 5-year annualized return is 22.02% (170.48% cumulative), indicating strong multi-year performance despite recent volatility.
What role do SPACs play in Mangrove Partners Im Llc’s portfolio?+
Mangrove holds a wide basket of SPAC and blank-check names, generally near trust value with modest gains versus cost. The quarter’s minimal trims and new small entries suggest the SPAC book is used as a low‑risk optionality and funding sleeve rather than a high‑conviction growth engine.